Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07796893
NA

Exosomal Markers CD63 and CD9 in Vitiligo Before and After NB-UVB Therapy

Sponsor: Amany El-Agamy Ibrahim El-Samadony

View on ClinicalTrials.gov

Summary

This study evaluated the expression of the exosomal markers CD63 and CD9 in the skin of patients with vitiligo and assessed changes in their expression after narrow-band ultraviolet B (NB-UVB) therapy. Twenty patients with vitiligo were included and received NB-UVB therapy for 3 months. Clinical disease activity and severity were assessed using the Vitiligo Disease Activity (VIDA) score and the Vitiligo Area Severity Index (VASI) before and after treatment. Before treatment, skin biopsies were obtained from lesional and perilesional skin. After treatment, skin biopsies were obtained from repigmented areas. The tissue specimens were evaluated histopathologically and by immunohistochemical staining for CD63 and CD9. Twenty normal skin specimens obtained during plastic surgery were used as healthy controls for comparison.

Official title: Expression of Exosomal Markers (CD63 and CD9) in Lesional Skin of Vitiligo Patients Before and After Narrow-Band Ultraviolet B Therapy: An Immunohistochemical Study

Key Details

Gender

All

Age Range

Any - Any

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2024-05-20

Completion Date

2026-01-01

Last Updated

2026-09-03

Healthy Volunteers

No

Conditions

Interventions

RADIATION

Narrow-Band Ultraviolet B (NB-UVB) Therapy

Participants with vitiligo received narrow-band ultraviolet B (NB-UVB) phototherapy for 3 months as the study intervention.

Locations (1)

Tanta University Hospitals

Tanta, Gharbia Governorate, Egypt